Montgomery County launches site to support businesses, workers
The initiative brings together county agencies, business organizations, and workforce development groups to provide resources, including job postings, business incentives, and financial assistance.
MoCo Minute | AstraZeneca acquires EsoBiotec in $1 Billion deal to advance cancer treatment
A new website, Mobilize-Montgomery.com, will serve as a central hub for affected businesses and employees.
County leaders said the coalition will work closely with the state to ensure continued support. As federal cuts ripple through the local economy, Mobilize Montgomery aims to keep businesses afloat and residents working.
For more information, click .
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Sophia Genetics SA (SOPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Sophia Genetics SA (NASDAQ:SOPH) reported a 16% year-over-year revenue growth, with a 20% increase when excluding biopharma, indicating strong performance in its core business. The company signed a record 35 new customers in Q2, bringing the total to 63 new customers for the year, showcasing strong business momentum. Sophia Genetics SA (NASDAQ:SOPH) announced a significant multi-year partnership with AstraZeneca, focusing on AI-powered predictive models for breast cancer treatment, highlighting its capabilities in AI and data analytics. The company achieved a 35% year-over-year reduction in cash burn, demonstrating improved financial efficiency. Sophia Genetics SA (NASDAQ:SOPH) reported a 74.4% adjusted gross margin, an improvement of 120 basis points year-over-year, reflecting effective cost management and platform optimization. Negative Points Biopharma sector continues to present headwinds, impacting overall revenue growth despite strong performance in other areas. Operating expenses increased by 19% year-over-year, driven by higher sales and marketing expenses and foreign exchange impacts. The company reported an adjusted operating loss of $12.6 million, a 27% increase from the previous year, indicating ongoing financial challenges. Sophia Genetics SA (NASDAQ:SOPH) experienced a 5% revenue churn, with some small accounts being churned out, which could affect future revenue stability. The company faces foreign exchange headwinds, which have impacted reported expenses and could continue to affect financial results due to macroeconomic uncertainties. Q & A Highlights Warning! GuruFocus has detected 4 Warning Signs with SOPH. Q: Can you provide more details on the AstraZeneca partnership and the milestones involved? A: The AstraZeneca partnership is a significant multi-year deal that validates our strategy in the biopharma market. It involves a series of deliverables over several quarters, with portions of the contract recognized based on the delivery of certain items and achievement of specific outcomes. We are confident in achieving the full value of this contract and delivering value to AstraZeneca. (Respondent: Unidentified_8) Q: What is the current status of your rare disease applications outside the US, and how does the competitive landscape look? A: About 20% of our business is in rare disorders, and we are seeing 20% year-on-year growth in this area. There is increasing demand for exomes and genomes globally, driven by advancements in hospital and lab technologies and scientific progress. Our AI capabilities enable labs to solve complex diagnostics in rare disorders, positioning us well in this competitive market. (Respondent: Unidentified_7) Q: Why did you decide to draw the $35 million revolver, and should we expect an increase in expenses? A: The decision to draw the revolver was made to strengthen our cash position, bringing our cash balance to nearly $95 million. This move ensures we have the liquidity needed to accommodate our accelerating growth across clinical and pharma sectors. (Respondent: Unidentified_10) Q: What are the adoption trends for MSK Access in the United States, and how quickly are customers getting up and running? A: Liquid biopsy is becoming clinically relevant, with significant interest in the US and globally. We have signed 11 new customers for MSK Access this quarter, bringing the total to 50. The US market is centralized, and our technology is well-suited for academic centers and central labs, with a 19% year-on-year growth in the US. (Respondent: Unidentified_7) Q: Can you provide more details on the terms of the perceptive financing? A: The financing is based on the secured overnight financing rate plus 6%. Perceptive received 200,000 warrants for each tranche of the financing. We have a positive relationship with Perceptive and may expand this relationship in the future. (Respondent: Unidentified_10) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Axios
10 hours ago
- Axios
Trump teases stepwise tariff plan for pharma
President Trump plans to levy a stepwise series of pharmaceutical tariffs that could reach 150% within a year and a half, then rise to 250%, he said in a wide-ranging interview on CNBC Tuesday. Why it matters: It's the highest tariff rate the president has threatened the industry with to date while he also presses major manufacturers to commit to a "most-favored nation" pricing policy. Trump previously threatened tariffs of up to 200%. Driving the news: "On pharmaceuticals, we'll be putting an initially small tariff," Trump told CNBC. "But within one year, one-and-a-half years maximum, it's going to go to 150%, and then it's going to go to 250% because we want pharmaceuticals made in our country," he said. An announcement is planned for as soon as this week, he said. Catch up quick: A number of drugmakers, including Eli Lilly, AstraZeneca, Johnson & Johnson and Roche, have made commitments to build up more U.S. manufacturing capability. But experts say it can take years to build new plants and shift product lines. A PhRMA spokesperson wouldn't comment on Trump's latest remarks, but the group has said tariffs on medicines would be "counterproductive." Of note: U.S. imports plunged again in June, largely due to a $9.6 billion decline in drug preparations, according to the new Census data.
Yahoo
20 hours ago
- Yahoo
Trump threatens 250pc tariffs on drug imports
Donald Trump has threatened to impose tariffs of up to 250pc on pharmaceutical imports in a major threat to one of Britain's key sectors. The US president, who has already warned global drugmakers to lower their domestic prices in the US, said he would be announcing tariffs for the industry 'within the next week or so'. Such a move could be damaging for the UK, which counts pharma giants AstraZeneca and GSK as two of its largest companies and employs 73,000 people in the sector overall. Britain has signed a trade agreement with the US but the pharmaceutical tariffs are expected to be outside the scope of the agreement, increasing the risk. 'We'll be putting an initially small tariff on pharmaceuticals but in one year, one and a half years maximum it's going to go to 150pc and then it's going to go to 250pc,' Mr Trump said in a US television interview on Tuesday. The president added that he would impose tariffs on pharmaceutical imports to the US 'because we want pharmaceuticals made in our country'. It marks a fresh threat to the industry, which is awaiting the outcome of an investigation by the US commerce department into the impact of imports on American national security. The US president said the tariffs on pharmaceutical imports would be 'a separate class' to a string of tariff deals announced in recent weeks, adding: 'These are excluded class, as I call them ... like steel, aluminium, etc.' Mr Trump has repeatedly made threats to impose various levels of tariffs on the industry before changing course. His latest comments on trade levies come just days before his latest tariff deadline on goods entering the US comes into effect on Aug 7. The president was also critical of India after the country's foreign ministry accused the US and the EU of double standards on buying Russian oil. The US is due to impose 25pc tariffs on imports from India but Trump threatened to lift this further in his latest escalation. 'We settled on 25pc but I think I'm going to raise that very substantially over the next 24 hours because they are buying Russian oil, they are fuelling the war machine, and if they're going do that I'm not going to be happy,' he said, adding that India had 'not been a good trading partner'. 'The sticking point with India is that tariffs are too high ... They will give us zero tariffs and they're going to let us go in but that's not good enough because of what they are doing with oil.' Mr Trump also renewed his attacks on Jerome Powell, the chairman of the Federal Reserve, and repeated his calls for the central bank to cut interest rates. 'Jay Powell is highly political and I call him ... Too Late Jerome, Too Late Powell,' he said. Mr Trump added that Scott Bessent, the US treasury secretary, 'does not want' to be chairman of the Federal Reserve but said that there were four others in the running for the position. Mr Powell's term as chairman of the Federal Reserve ends in May 2026. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
